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risk factors for survival and BCLC stage A was a good prognostic factor for OS in group
1 treated by TACE.
Conclusion: Serglycin in peripheral blood cells was increased significantly in HBV-
infected HCC patients. Average fluorescence intensity of serglycin in peripheral neutro-
phils was found to be an independent predictor of prognosis for HCC patients, not lim-
ited by infective complications, and was superior to other inflammation prognostic
factors. Based on the data from the current study, testing of serglycin levels could be a
simple and feasible way to predict prognosis for HCC patients with TACE.
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Introduction: Human kinesin centromere-associated protein E (CENP-E), a spindle
checkpoint protein, has been identified as a tumour suppressor. Although reduced
CENP-E expression has been reported in human hepatocellular carcinoma (HCC) tis-
sues, its role in hepatocarcinogenesis is unknown. To date, there is no evidence linking
reduced CENP-E expression to HCC initiation and development, nor any evidence
that low CENP-E in HCC has any clinical relevance. In this study, we investigated the
contribution of reduced CENP-E on HCC development and the clinical relevance of
low CENP-E in HCC patients.
Methods: HCC cell lines (SMMC7721 and QGY7701), animal xenograft models, and
90 human HCC tissues were used to investigate the importance of CENP-E as a tumour
suppressor. CENP-E was silenced using-shRNAs and validated by western blotting and
immunohistochemistry (IHC). In vitro effects were studied using cell proliferation,
migration, colony forming, and wound closure assays. Cell-cycle and cell apoptosis
were analysed by flow cytometry. The in vivo effect of down-regulated CENP-E on
tumour growth was examined in a xenograft tumour model. CENP-E expression in
HCC tissues was analysed by IHC. Analysis of patient survival was performed using
Kaplan–Meier analysis and Cox regression analysis (SPSS).
Results: We demonstrated that down-regulation of CENP-E by CENP-E-silencing
shRNAs significantly promoted HCC proliferation/growth both in vitro and in vivo.
CENP-E suppressed the proliferation of HCC cells by halting cell cycle progression at
the G1-S phase and accelerated cell apoptosis. Analyses of HCC patient samples/clinical
data revealed that CENP-E was significantly down-regulated in HCC tissues and low
CENP-E expression was significantly associated with patient adverse clinicopathologi-
cal features including poor prognosis, advanced TNM stage, metastasis, and larger
tumor size. Multivariate analysis indicated that CENP-E was an independent prognos-
tic factor predicting outcomes of advanced HCC patients.
Conclusion: Our data suggest that loss of CENP-E contributes to HCC development
and is strongly associated with the adverse clinical pathology of HCC. Thus CENP-E
could be a novel target for new treatments and a useful prognostic biomarker for HCC
patients.
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Introduction: The aim of this retrospective study is to evaluate feasibility, safety, toxic-
ity profile, and dosimetric results of volumetric modulated arc therapy (VMAT) to
deliver hypofractionated radiotherapy in locally advanced oesophageal cancer patients
unfit for a multimodality strategy.
Methods: From 2010 to 2017, twenty-two patients were treated with hypofractionated
VMAT for exclusive setting. Dose prescription of 40 Gy in 16 fractions (EQD2 41.7 Gy
considering an alpha/beta of 10 and 44 Gy considering an alpha/beta of 3) depended on
the clinical scenario of locally advanced disease and patients unfit for a standard neoad-
juvant/definitive treatment.
Results: Eight patients were in stage IVB (36%) and 14 (64%) were in stage II-III. Eight
patients (36%) presented with grade 3 baseline dysphagia according to the Common
Terminology Criteria for Adverse Events, version 4.02. Radiotherapy was generally
well-tolerated and with no interruptions of daily treatment. Acute toxicity was
generally mild. According to the to RTOG/EORTC toxicity scale, G1 toxicities were
observed for weight loss (32%), fatigue (59%), and nausea/vomiting (18%). During
treatment, 86% of patients experienced stability or improvement of baseline dysphagia,
while only 3 patients reported a worsening of esophagitis. Among the 19 patients suit-
able for short-term follow-up, 15 (79%) had a complete clinical recovery (G0-1) of the
symptomatic moderate/severe dysphagia. Mean overall survival was 8.7 months (range
1-43 months). Two coplanar arcs were employed for VMAT delivery. Dosimetric
results were consistent in terms of both target coverage and normal tissue sparing. The
95% isodose of the prescribed dose (40 Gy) closely encompassed the all planning target
volumes (PTVs), and volumes receiving> 107% of the prescribed dose were mini-
mized below 2%. Dose parameters for organs at risk were set to respect the thresholds
for spinal cord, lungs, heart, stomach, bowel, and kidneys. For setup verification, kilo-
voltage cone-beam CT image-guidance was employed for all patients.
Conclusion: Hypofractionated VMAT was feasible, safe, and effective to deliver defini-
tive radiation in locally advanced oesophageal cancer patients, non-suitable for stand-
ard treatment.
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Introduction: Primary malignant tumors of the small intestine are rare tumors. They
represent 1 to 5% of all tumors of the digestive tract, despite the small intestine
accounting for 75% of the total length and more than 90% of the mucosal surface of the
digestive tract. The multiplicity of histological types associated with the rarity of these
tumors and the absence of prospective randomized trials elucidating the best diagnostic
and therapeutic options make it difficult to establish valid statistics. The small intestine
is considered a clinically silent area, resulting in a delayed diagnosis and therefore a
non-optimal treatment and severe prognosis.
Methods: A retrospective study of 20 patients with bowel cancer heals over a period of
6 years spanning 2012 to 2018. The diagnosis of pelvic cancer was based on an anato-
mopathological study of either the piece of intestinal surgical resection or on a tumor
biopsy. All patients with histological confirmation of a malignant tumor of the duode-
num until the terminal ileum were included in the study
Results: We collected 20 cases of tumors of the small intestine over 6 years. Forty-six
percent of the patients were less than 50 years old. The age of patients with small bowel
tumor at the time of diagnosis ranged from 23 to 76 years with an average of 46 years.
Fourteen patients were male and 6 were female, with a sex ratio of 2.2. One case of celiac
disease was reported according to patient history. Melena with abdominal pain led to
tumor discovery in more than half of cases (52%), followed by chronic vomiting
(18%), tumor syndrome with 4 abdominal masses (10%) and 3 cases of occlusive syn-
drome (11%). Weight loss occurred in 80% of patients. A CT scan performed in 13
patients showed hail wall thickening localized in 70% of cases and staged in 5% of cases.
Localized stenosis occurred in 11% and tissue mass in 14%. Pathological features of
small bowel tumors included stromal tumors in 50% of cases, followed by adenocarci-
noma (27%), and neuroendocrine carcinoma (13%). More than 50% of the pelvic can-
cers were in the jejunum. The treatment of choice still remains surgery and represents
the only potentially curative treatment of these tumors. The overall resectability rate
was 75%, Imatinib treatment was initiated in patients with stromal tumors in adjuvant
therapy or metastasis.
Conclusion: The management of small intestine tumors remains a diagnostic and ther-
apeutic challenge and the only curative treatment is surgical excision. Therapy with
tyrosine kinase inhibitors (imatinib) was introduced and showed very good results in
terms of survival.
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